Public Safety

September 1, 2022 | Fact Sheets, Novel Psychoactive Substances, Opioids, Public Safety, Stimulants, Substance Misuse, Synthetic Drugs

The Legislative Analysis and Public Policy Association is monitoring the emergence of novel psychoactive substances appearing on the illicit drug market in the United States. The term “novel” does not denote a new, never-before-seen substance but rather a substance that is newly available in the drug market. This fact sheet,  examines pyro, a relatively new high potency synthetic opioid increasing in prevalence in the U.S. Pyro belongs to an opioid subclass of NPS called 2-benezylbenzimidazoles, or nitazenes, and is structurally similar to etonitazene, a synthetic opioid that is nationally and internationally controlled. N-pyrrolidino etonitazene is not described or mentioned in any medical literature or patents, meaning that it is a truly “novel” NPS and likely developed independently from the pharmaceutical industry. Researchers believe that N-pyrrolidino etonitazene is coming to the U.S. via purchases on the dark web and is likely being produced in China. N-pyrrolidino etonitazene can be found in powder form or pressed into pills to resemble other substances. Studies estimate that N-pyrrolidino etonitazene is over 800 times more potent than morphine and 20-40 times more potent than fentanyl. Like other opioids, N-pyrrolidino etonitazene use can potentially cause fatal respiratory depression in the person ingesting the drug. However, because...

April 14, 2022 | Fact Sheets, First Responders, Harm Reduction, Naloxone, Opioid Antagonists, Opioids, Public Health, Public Safety, Sharps/Syringes

Naloxone is an emergency opioid antagonist that works by reversing the effects of an opioid overdose. Specifically, naloxone prevents decreased breathing which typically happens when someone overdoses on an opioid and must be given when someone shows the first sign of an overdose. Naloxone access laws delineate how someone may legally access naloxone in a particular state or jurisdiction. This includes which individuals can prescribe, dispense, or administer naloxone and what forms of civil or criminal immunity are provided, if any, for the use of the opioid reversal drug. All 50 states and the District of Columbia have some form of naloxone access law. This fact sheet provides readers with an overview of what naloxone is and a brief overview of naloxone access law across the United States....

March 28, 2022 | Controlled Substances, Criminal Justice, Drug Courts, Law Enforcement, Opioids, Prescription Drugs, Public Health, Public Safety, Recovery, Reports & Studies, Substance Misuse, Synthetic Drugs

In September 2021, Georgetown University Law Center convened an Opioid Litigation Summit. This convening brought together numerous experts to discuss legal, administrative, and programmatic strategies needed to optimize the impact of proceeds from the opioid litigation. The themes described in this brief emerged from the Summit and can be applied to the opioid litigation as well as future mass tort litigation to address public health crises....

March 2, 2022 | Controlled Substances, Criminal Justice, Drug Courts, First Responders, Harm Reduction, Law Enforcement, Model Laws, Public Health, Public Safety, Recovery, Substance Misuse, Treatments

 Drafted in partnership with the Police, Treatment, and Community Collaborative (PTACC), the Model Law Enforcement and Other First Responder Deflection Act, encourages the use and establishment of deflection programs on the state level. Specifically, the model act (1) authorizes law enforcement and other first responders to develop and implement collaborative deflection programs that provide proactive policing to assist individuals who are at risk; (2) offers pathways to treatment, recovery services, housing, medication for addiction treatment, whole family services, and other needed supports; (3) requires deflection programs to have certain threshold elements to be eligible to receive grant funding; and (4) requires agencies establishing deflection programs to develop comprehensive memoranda of understanding in conjunction with, and agreed to by, all deflection program partners....

December 7, 2021 | Controlled Substances, Harm Reduction, Model Laws, Opioids, Public Health, Public Safety, Sharps/Syringes, Substance Misuse

The Model Syringe Services Program Act authorizes the establishment of comprehensive syringe services programs, which are associated with a decrease in bloodborne infectious disease diagnoses as well as the number of needlestick injuries to first responders and others. This Act delineates the required components for syringe services programs operating within a state, including that such programs: (1) directly provide, or offer referrals to, expanded services, such as substance use disorder treatment, including medications for addiction treatment, HIV and viral hepatitis testing and treatment services, access to opioid antagonist kits, health care services, and mental health services; (2) reduce needlestick injuries to law enforcement, emergency services personnel, sanitation workers, and members of the community; (3) provide data collection and reporting requirements for syringe services programs; (4) provide immunity from criminal arrest, charge, and prosecution for the possession, distribution, or furnishing of hypodermic needles and syringes and other supplies; (5) provide educational and training materials for members of the community, including law enforcement and other first responders, such as emergency medical services; and (6) provide for funding of syringe services programs....